Business
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Corporation\") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 (\"Restated MD&A\"), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corporation, has determined that the Corporation’s previously filed management’s discussion and analysis for the for the financial year ended November 30, 2019 (\"Previously Filed MD&A\") needed to be restated to incorporate disclosure on the COVID-19 pandemic and its impact on the general business of Tetra. The Previously Filed MD&A was originally filed by the Corporation on SEDAR on March 25, 2020. The Restated MD&A replaces and supersedes the Previously Filed MD&A. Such Previously Filed MD&A should be disregarded. About Tetra Bio-Pharma:Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Corporation has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. Could we work in “existing regulatory standards of safety and clinical evidence for pharmaceutical products” More information at: www.tetrabiopharma.com Source: Tetra Bio-Pharma Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-looking statementsSome statements in this release may contain forward-looking information. All statements, othe...